IS5465A - Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum - Google Patents

Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum

Info

Publication number
IS5465A
IS5465A IS5465A IS5465A IS5465A IS 5465 A IS5465 A IS 5465A IS 5465 A IS5465 A IS 5465A IS 5465 A IS5465 A IS 5465A IS 5465 A IS5465 A IS 5465A
Authority
IS
Iceland
Prior art keywords
bioisosterone
indazole
catechol
conversion
active compounds
Prior art date
Application number
IS5465A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5465A publication Critical patent/IS5465A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5465A 1997-11-04 2000-04-19 Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum IS5465A (is)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6422897P 1997-11-04 1997-11-04
US6422997P 1997-11-04 1997-11-04
US6419897P 1997-11-04 1997-11-04
US6402497P 1997-11-04 1997-11-04
US6418797P 1997-11-04 1997-11-04
PCT/IB1998/001710 WO1999023077A1 (en) 1997-11-04 1998-10-26 Indazole bioisostere replacement of catechol in therapeutically active compounds

Publications (1)

Publication Number Publication Date
IS5465A true IS5465A (is) 2000-04-19

Family

ID=27535645

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5465A IS5465A (is) 1997-11-04 2000-04-19 Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum

Country Status (29)

Country Link
US (1) US6391872B1 (is)
EP (1) EP1028946A1 (is)
JP (1) JP2001521926A (is)
CN (1) CN1284948A (is)
AP (1) AP910A (is)
AR (1) AR013746A1 (is)
AU (1) AU754734B2 (is)
BG (1) BG104450A (is)
BR (1) BR9813926A (is)
CA (1) CA2309150A1 (is)
CZ (1) CZ20001621A3 (is)
DZ (1) DZ2640A1 (is)
EA (1) EA200000488A1 (is)
HR (1) HRP20000253A2 (is)
HU (1) HUP0004150A3 (is)
ID (1) ID23921A (is)
IL (1) IL135900A0 (is)
IS (1) IS5465A (is)
MA (1) MA26563A1 (is)
NO (1) NO20002129L (is)
NZ (1) NZ503918A (is)
OA (1) OA11354A (is)
PE (1) PE129199A1 (is)
PL (1) PL340753A1 (is)
SK (1) SK6252000A3 (is)
TN (1) TNSN98200A1 (is)
TR (1) TR200001234T2 (is)
WO (1) WO1999023077A1 (is)
YU (1) YU25000A (is)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716978B2 (en) * 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
JP2003507342A (ja) * 1999-08-12 2003-02-25 アメリカン・サイアナミド・カンパニー 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
AU2002255263B2 (en) 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
NZ532278A (en) 2001-09-19 2006-02-24 Altana Pharma Ag Combination of a PDE inhibitor and an NSAID
WO2003024456A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
AU2003201149A1 (en) * 2002-02-13 2003-09-04 Koninklijke Philips Electronics N.V. Integrated semiconductor optical device, method and apparatus for manufacturing such a device
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
EP2108370A1 (en) * 2002-04-30 2009-10-14 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
BR0316950A (pt) 2002-12-02 2006-01-17 Hoffmann La Roche Derivados de indazol como antagonistas de crf
BRPI0407253A (pt) * 2003-02-14 2006-01-31 Wyeth Corp Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20040220119A1 (en) * 2003-04-04 2004-11-04 Unigen Pharmaceuticals, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
RU2006134022A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
US7844309B2 (en) * 2004-02-27 2010-11-30 Nokia Corporation Exchangeable keymat
CA2557575A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CA2558109A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
CN101111494A (zh) * 2004-11-29 2008-01-23 沃纳-兰伯特有限公司 具有治疗作用的吡唑并[3,4-b]吡啶和吲唑
NZ565872A (en) * 2005-08-15 2011-06-30 Wyeth Corp Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007032833A1 (en) * 2005-08-15 2007-03-22 Wyeth Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007023111A2 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP2628725A1 (en) * 2005-11-03 2013-08-21 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
CN101370775A (zh) 2006-01-13 2009-02-18 惠氏公司 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
SI1981851T1 (sl) 2006-01-31 2012-05-31 Array Biopharma Inc Kinazni inhibitorji in postopki za njihovo uporabo
US7829713B2 (en) 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
US8084485B2 (en) 2006-03-31 2011-12-27 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
EP2001865A1 (en) * 2006-04-05 2008-12-17 Wyeth a Corporation of the State of Delaware Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US8558016B2 (en) * 2009-09-18 2013-10-15 Kabaushiki Kaisha Riverson Polyphenol derivative and method for producing the same
EP2569301A1 (en) 2010-05-12 2013-03-20 Abbvie Inc. Indazole inhibitors of kinase
CN103709146B (zh) * 2014-01-15 2015-11-25 中国药科大学 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338087A4 (en) * 1987-10-13 1991-07-24 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
WO1989003385A1 (fr) * 1987-10-13 1989-04-20 Yoshitomi Pharmaceutical Industries, Ltd. Composes de pyrazole fusionnes, procede de preparation et utilisation en medecine
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
EP0912558B1 (en) * 1996-06-25 2003-07-09 Pfizer Inc. Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
DE69709493T2 (de) * 1996-06-27 2002-10-31 Pfizer Inc., New York Substituierte Indazolderivate
CA2264798A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
US6716978B2 (en) * 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors

Also Published As

Publication number Publication date
PL340753A1 (en) 2001-02-26
TNSN98200A1 (fr) 2005-03-15
TR200001234T2 (tr) 2000-08-21
DZ2640A1 (fr) 2003-03-08
WO1999023077A1 (en) 1999-05-14
EA200000488A1 (ru) 2000-10-30
NO20002129L (no) 2000-07-03
AU9455298A (en) 1999-05-24
OA11354A (en) 2003-12-23
HUP0004150A2 (hu) 2001-05-28
NO20002129D0 (no) 2000-04-26
JP2001521926A (ja) 2001-11-13
IL135900A0 (en) 2001-05-20
HUP0004150A3 (en) 2001-08-28
YU25000A (sh) 2003-12-31
BR9813926A (pt) 2000-09-19
ID23921A (id) 2000-05-25
CA2309150A1 (en) 1999-05-14
EP1028946A1 (en) 2000-08-23
CZ20001621A3 (cs) 2001-08-15
AP910A (en) 2000-12-05
NZ503918A (en) 2002-03-28
US6391872B1 (en) 2002-05-21
BG104450A (en) 2000-12-29
MA26563A1 (fr) 2004-12-20
SK6252000A3 (en) 2001-11-06
AP9801375A0 (en) 1998-12-31
CN1284948A (zh) 2001-02-21
HRP20000253A2 (en) 2001-06-30
PE129199A1 (es) 1999-12-16
AU754734B2 (en) 2002-11-21
AR013746A1 (es) 2001-01-10

Similar Documents

Publication Publication Date Title
IS5465A (is) Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum
DE69824231D1 (de) Bioadhäsive Tabletten
IS5595A (is) Úðagjöf á virkum efnum
FI972555L (fi) Päällystettyjen tablettien valmistus
ID25629A (id) AMINA BISIKLIK (Pecahan dari P-961362)
ID24247A (id) Penjajaran cetakan tunggal
IS5452A (is) Meðferðarlega virk efnasambönd byggð á indazól bíóísóstera skiptum á katekóli í PDE4 lötum
ID23018A (id) Proses baru untuk pembuatan zat-zat yang aktif secara farmakologi
DE59707194D1 (de) Direkttablettierhilfsmittel
IS5148A (is) Efnasambönd til að hindra magasýruseytrun
ID24417A (id) Ariloksi-alkil-dialkilamina yang baru
NO984290D0 (no) Farmas°ytisk nyttige forbindelser
ID26317A (id) Formulasi pelepasan yang diperpanjang
ID22233A (id) Tablet telan yang terdiri dari parasetamol
BR9802203A (pt) Compostos precursores
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
NO983090D0 (no) Terapeutiske forbindelser
ID23885A (id) Bentuk-bentuk polimorf baru dari cypamfylline
ATE240096T1 (de) Schnellfreisetzende komprimierte flurbiprofen enthaltende tablette
SE9704874D0 (sv) New pharmaceutically active compounds
SE9700660D0 (sv) Pharmaceutically active compounds
KR960037383U (ko) 트랜스퍼용 주행빔의 연결구조
NO20000815D0 (no) Virkestoffholdig vekesystem
ID19095A (id) Senyawa terapeutik fenetanolamina
SE9802539D0 (sv) New pharmaceutically active compounds